[
  {
    "ts": null,
    "headline": "Revvity (RVTY) Up 9.5% Since Last Earnings Report: Can It Continue?",
    "summary": "Revvity (RVTY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
    "url": "https://finnhub.io/api/news?id=0512079e891434afd901c90ce6212d1ebf311b0e1e47845cacb239169ef6513d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764174607,
      "headline": "Revvity (RVTY) Up 9.5% Since Last Earnings Report: Can It Continue?",
      "id": 137614597,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DHR",
      "source": "Yahoo",
      "summary": "Revvity (RVTY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
      "url": "https://finnhub.io/api/news?id=0512079e891434afd901c90ce6212d1ebf311b0e1e47845cacb239169ef6513d"
    }
  },
  {
    "ts": null,
    "headline": "Danaher Stock: Is DHR Underperforming the Healthcare Sector?",
    "summary": "Despite Danaher’s underperformance relative to the healthcare sector, Wall Street analysts remain strongly optimistic about the stock’s prospects.",
    "url": "https://finnhub.io/api/news?id=57d07de9f7e3177c881f31b9782db972c147b4da961d69e2c474d5a2300402ce",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764161309,
      "headline": "Danaher Stock: Is DHR Underperforming the Healthcare Sector?",
      "id": 137614598,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DHR",
      "source": "Yahoo",
      "summary": "Despite Danaher’s underperformance relative to the healthcare sector, Wall Street analysts remain strongly optimistic about the stock’s prospects.",
      "url": "https://finnhub.io/api/news?id=57d07de9f7e3177c881f31b9782db972c147b4da961d69e2c474d5a2300402ce"
    }
  },
  {
    "ts": null,
    "headline": "US STD Diagnostics Market Forecast and Company Analysis 2025-2033 Featuring Abbott, F. Hoffmann-La Roche, Hologic, BD and Co, Danaher, Siemens, bioMerieux, Thermo Fisher Scientific, Qiagen, Bio-Rad",
    "summary": "The United States STD Diagnostics Market is set to grow from US$ 5.06 billion in 2024 to US$ 8.49 billion by 2033, achieving a CAGR of 5.91% from 2025 to 2033. Key growth drivers include rising STD prevalence, technological advancements, increased awareness, and supportive government initiatives. Rapid point-of-care tests and molecular diagnostics are gaining traction, while high costs and regulatory hurdles persist as challenges. Major markets like California, Texas, New York, and Florida lead",
    "url": "https://finnhub.io/api/news?id=8543e594ef4f6888b8a60fd6caa1d759c601038a6cd2405c9742a3e70a98035d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764152220,
      "headline": "US STD Diagnostics Market Forecast and Company Analysis 2025-2033 Featuring Abbott, F. Hoffmann-La Roche, Hologic, BD and Co, Danaher, Siemens, bioMerieux, Thermo Fisher Scientific, Qiagen, Bio-Rad",
      "id": 137611362,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DHR",
      "source": "Yahoo",
      "summary": "The United States STD Diagnostics Market is set to grow from US$ 5.06 billion in 2024 to US$ 8.49 billion by 2033, achieving a CAGR of 5.91% from 2025 to 2033. Key growth drivers include rising STD prevalence, technological advancements, increased awareness, and supportive government initiatives. Rapid point-of-care tests and molecular diagnostics are gaining traction, while high costs and regulatory hurdles persist as challenges. Major markets like California, Texas, New York, and Florida lead",
      "url": "https://finnhub.io/api/news?id=8543e594ef4f6888b8a60fd6caa1d759c601038a6cd2405c9742a3e70a98035d"
    }
  }
]